This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Big Screen: Funds That Have Given Themselves a Booster Shot

It's often said that fund managers' favorite game is follow the leader. And this year health care stocks have been the leader.

Since Jan. 1, health care sector funds are up 40.9%, on average. That's nearly double the 21.9% rise of the runner-up sector, real estate, and it trounces the 6.9% average gain for technology sector funds.

If health care stocks keep their torrid pace, and if history is any guide, many of those stocks will be turning up in your portfolio -- even if you don't own a health care sector fund.

After technology-sector funds gained an average of 137% in 1999, growth fund managers this year plowed an average of 44% of their funds' assets into the sector, according to Morningstar.

So keep an eye on your portfolio's sector allocations. If several of your funds start gobbling up more health care stocks and you already own a health care fund, you should be wary of becoming overexposed to the sector. Some funds have already started increasing their health care stake, as we see in this week's The Big Screen.

Here are the 10 diversified growth funds with health care weightings that have jumped the most over the last 18 months or so. To make our list, a fund had to be diversified (that is, not focused on a particular sector), and its most recent portfolio information had to be made public at least as recently as June 30.

Healthy Returns?
Here are the 10 growth funds that have raised their stake in health care stocks the most since 1998.
Fund June 30
Health Care Stake
Health Care Stake
YTD Return
(NAEGX) 24.2% 9.3% 3.9%
(HAGAX) 21.4 0.9 19.1
(NSOAX) 21 10.5 26
(TGMOX) 20.5 11.1 -0.3
(TAEMX) 20 10.6 -3.1
(QUASX) 18.8 5.8 3.2
(TGCEX) 18 6.2 18
(AGTHX) 17.2 7.5 20.9
(PSMCX) 15.4 3.7 3.8
(SEGAX) 14.1 5.1 3.9
S&P 500 11 10.8 1.6
Source: Morningstar and Baseline. Performance figures through Aug. 17.

All but three of the funds on the list ( (SEGAX), (AGTHX), and (TGCEX)) are composed of mostly small-cap stocks, according to Morningstar. That makes sense because much of the action in the health care sector has been among small biotechnology companies -- the cutting-edge labs where new drugs are developed.

The Human Genome Project, a private/public effort to map human genes making it easier to pinpoint the roots of disease, has clearly struck a chord with investors. Over the last 12 months the American Stock Exchange Biotechnology Index is up 156%; it has risen 71.9% since Jan. 1.

Bigger-cap pharmaceutical stocks, which often have a tough time in election years, haven't been such rockets. The American Stock Exchange Pharmaceutical Index is up just 13% this year, according to Baseline. (For a more detailed look at the sector, see this week's 10 Questions interview with veteran (MAHCX) manager Jordan Schreiber.)

As you can see from the variance in returns among the funds on the list, upping an allocation to a hot sector doesn't guarantee hot performance. Also, many of these funds' managers haven't been on board for three years, so in some cases the shift toward health care could have more to do with a new manager's tastes than with any bandwagon mentality.

Some of the better-performing small-cap funds on the list have added stocks this year like COR Therapeutics (CORR - Get Report) ( (NAEGX)), Lexicon Genetics (LEXG)( (HAGAX)), and Community Health Systems (CYH) ( (NSOAX)). COR Therapeutics is up a whopping 234% so far this year, while Lexicon and Community Health are recent IPOs .

Perhaps the most intriguing name on the list is the $36.8 billion Growth Fund of America, which has racked up a gain of 20% this year despite its girth, according to Morningstar, while its average peer has flat returns. It is part of the low-profile but well-regarded American Funds fleet and is the eighth-largest fund in the nation.

Most recently, the fund's management team built up its positions in big-cap pharmaceutical houses Pfizer (PFE - Get Report) and Pharmacia (PHA), which are up 36.6% and 69% this year, respectively.

Of course, the opposite of these growth funds are those that have significantly reduced their stake in health care stocks over the last 18 months. Here's a list of the five growth funds that have headed most drastically away from the sizzling sector.

Some Like It Cool
The five growth funds that have reduced their health care stake the most since 1998.
Fund June 30
Health Care Stake
Health Care Stake
YTD Return
(ENCAX) 5.5% 27.7% -2.4%
(EATRX) 13.1 29.8 2.9
(NMGAX) 4.3 27.3 56.6
(SRFCX) 2.3 20.5 13
(OSTAX) 0.9 18.5 22.9
S&P 500 11 10.8 1.6
Source: Morningstar and Baseline. Performance figures through Aug. 18.

Again we see another wide range of results this year, showing that sector shifts don't necessarily predict performance. An interesting fund on this list is broker-sold (NMGAX). The little-known fund has been run by tech specialist Aaron Harris since April.

You might remember that Harris helped manage the institutional (NGTIX) fund, which was 1999's No. 1 fund with a jaw-dropping 494% return. More than 80% of the fund is now in tech stocks, and it has returned 41.1% over the last three months, beating virtually every other mid-cap growth fund.

There you have it, some funds that are doubling their dosage of health care stocks and others that are treating them like the plague. If you own funds that are in either camp and ignore the diversification challenges they raise, you could unwittingly end up with an imbalance of health care stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CORR $11.91 0.00%
PFE $29.36 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs